+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myelodysplastic Syndrome - Pipeline Review, H2 2019

  • ID: 4894225
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1542 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • BioLineRx Ltd
  • Denovo Biopharma LLC
  • Imago BioSciences Inc
  • MediGene AG
  • Onxeo SA
  • MORE
Myelodysplastic Syndrome - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 84, 63, 2, 8, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 9, 4 and 3 molecules, respectively.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • BioLineRx Ltd
  • Denovo Biopharma LLC
  • Imago BioSciences Inc
  • MediGene AG
  • Onxeo SA
  • MORE
Introduction
Myelodysplastic Syndrome - Overview
Myelodysplastic Syndrome - Therapeutics Development
Myelodysplastic Syndrome - Therapeutics Assessment
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
Myelodysplastic Syndrome - Drug Profiles
Myelodysplastic Syndrome - Dormant Projects
Myelodysplastic Syndrome - Discontinued Products
Myelodysplastic Syndrome - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..7), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2019
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H2 2019
Myelodysplastic Syndrome - Pipeline by Altor Bioscience LLC, H2 2019
Myelodysplastic Syndrome - Pipeline by Amphivena Therapeutics Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H2 2019
Myelodysplastic Syndrome - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Myelodysplastic Syndrome - Pipeline by Apogenix AG, H2 2019
Myelodysplastic Syndrome - Pipeline by Aprea Therapeutics AB, H2 2019
Myelodysplastic Syndrome - Pipeline by AptaBio Therapeutics Inc, H2 2019

List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • AbbVie Inc
  • Acceleron Pharma Inc
  • Actinium Pharmaceuticals Inc
  • Aeglea BioTherapeutics Inc
  • Agios Pharmaceuticals Inc
  • AIMM Therapeutics BV
  • Altor Bioscience LLC
  • Amphivena Therapeutics Inc
  • Angiocrine Bioscience Inc
  • Anhui Anke Biotechnology (Group) Co Ltd
  • Apogenix AG
  • Aprea Therapeutics AB
  • AptaBio Therapeutics Inc
  • Aptevo Therapeutics Inc
  • Aptose Biosciences Inc
  • Argenx SE
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • BerGenBio ASA
  • Bio-Path Holdings Inc
  • BioLineRx Ltd
  • BioMed Valley Discoveries Inc
  • Bionetix Inc
  • BioTheryX Inc
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • Celgene Corp
  • CellCentric Ltd
  • Cellenkos Inc
  • Cellerant Therapeutics Inc
  • Celularity Inc
  • Celyad SA
  • CheckPoint Immunology Inc
  • ChemioCare USA Inc
  • Chimerix Inc
  • China NT Pharma Group Co Ltd
  • Chordia Therapeutics Inc
  • Constellation Pharmaceuticals Inc
  • CrystalGenomics Inc
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • DC Prime BV
  • Deciphera Pharmaceuticals Inc
  • Denovo Biopharma LLC
  • DiNonA Inc
  • Eli Lilly and Co
  • Elixirgen Therapeutics LLC
  • ExCellThera Inc
  • Fate Therapeutics Inc
  • Forma Therapeutics Inc
  • Fortress Biotech Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corp
  • Gadeta BV
  • Gamida Cell Ltd
  • Geron Corp
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • GT Biopharma Inc
  • H3 Biomedicine Inc
  • Helocyte Biosciences Inc
  • HemoGenyx LLC
  • iCell Gene Therapeutics LLC
  • IGF Oncology LLC
  • Imago BioSciences Inc
  • Immune System Key Ltd
  • ImmunoGen Inc
  • Incysus Therapeutics Inc
  • Incyte Corp
  • Inmune Bio Inc
  • Io Therapeutics Inc
  • Iterion Therapeutics
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Jubilant Biosys Ltd
  • Juno Therapeutics Inc
  • Kainos Medicine Inc
  • Karyopharm Therapeutics Inc
  • Kiadis Pharma NV
  • Les Laboratoires Servier SAS
  • Lixte Biotechnology Holdings Inc
  • MacroGenics Inc
  • Magenta Therapeutics Inc
  • Mana Therapeutics Inc
  • Marker Therapeutics Inc
  • Mateon Therapeutics Inc
  • MediGene AG
  • Medivir AB
  • MedPacto Inc
  • MEI Pharma Inc
  • Merck & Co Inc
  • Merus NV
  • Millennium Pharmaceuticals Inc
  • Molecular Templates Inc
  • Mustang Bio Inc
  • Nanjing Legend Biotech Co Ltd
  • NantKwest Inc
  • Nemucore Medical Innovations Inc
  • Newave Pharmaceutical Inc
  • NexImmune Inc
  • Nkarta Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • Oncoceutics Inc
  • Oncoheroes Biosciences Inc
  • Onconova Therapeutics Inc
  • Oncotelic Inc
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Opsona Therapeutics Ltd
  • Orca Biosystems Inc
  • Orsenix Holdings BV
  • Oxstem Ltd
  • PersImmune Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • Prelude Therapeutics Inc
  • PRISM Pharma Co Ltd
  • Protagonist Therapeutics Inc
  • Rafael Pharmaceuticals Inc
  • Selvita SA
  • Sensei Biotherapeutics Inc
  • Senz Oncology Pty Ltd
  • Shanghai Yingli Pharmaceutical Co Ltd
  • Silence Therapeutics Plc
  • Sino Biopharmaceutical Ltd
  • SpecificiT Pharma Inc
  • Stelexis Therapeutics LLC
  • Stemline Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Surface Oncology Inc
  • Syntrix Biosystems Inc
  • Takara Bio Inc
  • Teva Pharmaceutical Industries Ltd
  • TheraPharm Deutschland GmbH
  • Toko Pharmaceutical Industries Co Ltd
  • Tolero Pharmaceuticals Inc
  • TOT Biopharm Co Ltd
  • Trethera Corp
Note: Product cover images may vary from those shown
Adroll
adroll